Evidence map›Paper›PMID 22969728›Full record

ArticleFrontiers in physiology2012

A Systems Biology Approach to Deciphering the Etiology of Steatosis Employing Patient-Derived Dermal Fibroblasts and iPS Cells.

Justyna Jozefczuk, Karl Kashofer, Ramesh Ummanni, Frauke Henjes, Samrina Rehman, Suzanne Geenen, Wasco Wruck, Christian Regenbrecht, Andriani Daskalaki, Christoph Wierling and 7 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in physiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 9 institutions in 5 countries.

Justyna JozefczukDepartment of Vertebrate Genomics, Max Planck Institute for Molecular Genetics Berlin, Germany.
Karl Kashofer
Ramesh Ummanni
Frauke Henjes
Samrina Rehman
Suzanne Geenen
Wasco Wruck
Christian Regenbrecht
Andriani Daskalaki
Christoph Wierling
Paola Turano
Ivano Bertini
Ulrike Korf
Kurt Zatloukal
Hans V Westerhoff
Hans Lehrach
James Adjaye
Max Planck Institute for Molecular Genetics · DECharité - Universitätsmedizin Berlin · DEHeidelberg University · DEMedical University of Graz · ATGerman Cancer Research Center · DEHeinrich Heine University Düsseldorf · DEInteruniversity Consortium for Magnetic Resonance · ITUniversity of Amsterdam · NLUniversity of Florence · IT

Funding

Biotechnology and Biological Sciences Research Council BB/C008219/1Biotechnology and Biological Sciences Research Council BB/I004688/1
6 · The paper itself

Abstract

Non-alcoholic fatty liver disease comprises a broad spectrum of disease states ranging from simple steatosis to non-alcoholic steatohepatitis. As a result of increases in the prevalences of obesity, insulin resistance, and hyperlipidemia, the number of people with hepatic steatosis continues to increase. Differences in susceptibility to steatohepatitis and its progression to cirrhosis have been attributed to a complex interplay of genetic and external factors all addressing the intracellular network. Increase in sugar or refined carbohydrate consumption results in an increase of insulin and insulin resistance that can lead to the accumulation of fat in the liver. Here we demonstrate how a multidisciplinary approach encompassing cellular reprogramming, transcriptomics, proteomics, metabolomics, modeling, network reconstruction, and data management can be employed to unveil the mechanisms underlying the progression of steatosis. Proteomics revealed reduced AKT/mTOR signaling in fibroblasts derived from steatosis patients and further establishes that the insulin-resistant phenotype is present not only in insulin-metabolizing central organs, e.g., the liver, but is also manifested in skin fibroblasts. Transcriptome data enabled the generation of a regulatory network based on the transcription factor SREBF1, linked to a metabolic network of glycerolipid, and fatty acid biosynthesis including the downstream transcriptional targets of SREBF1 which include LIPIN1 (LPIN) and low density lipoprotein receptor. Glutathione metabolism was among the pathways enriched in steatosis patients in comparison to healthy controls. By using a model of the glutathione pathway we predict a significant increase in the flux through glutathione synthesis as both gamma-glutamylcysteine synthetase and glutathione synthetase have an increased flux. We anticipate that a larger cohort of patients and matched controls will confirm our preliminary findings presented here.

Indexed as

AKT/mTOR signalingglutathione metabolisminduced pluripotent stem cellslipid metabolismmodelingNAFLDsterol biosynthesissystems biology

Identifiers

PMID22969728
PMCPMC3432516
OpenAlexW2138205299

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.